Related Experiment Video
Updated: Jun 30, 2026
12:25
Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
Published on: March 3, 2014
Botulinum toxin products overview
1Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
Skin Therapy Letter
|September 23, 2008
Summary
Botulinum toxin type A, known as BOTOX(R), is a highly successful cosmetic treatment for wrinkle reduction. Its popularity has spurred the development of new neurotoxins for facial rejuvenation.
Area of Science:
- Aesthetic Medicine
- Dermatology
- Neurology
Background:
- Botulinum toxin type A (BOTOX(R)) has achieved significant success in cosmetic applications.
- It is a leading non-surgical procedure for wrinkle reduction globally.
- Physicians across specialties incorporate botulinum toxin injections into their practices for facial rejuvenation.
Purpose of the Study:
- To provide an overview of botulinum toxin products used in cosmetic applications.
- To discuss products that have received regulatory approval.
- To highlight neurotoxins currently under development for cosmetic use.
Main Methods:
- Literature review of approved and developmental botulinum toxin products.
- Analysis of market trends and clinical applications in aesthetic medicine.
- Synthesis of information on neurotoxin efficacy and safety for cosmetic purposes.
Main Results:
- Botulinum toxin type A remains the dominant product in the cosmetic market.
- Several other botulinum toxin formulations are approved or in development.
- The demand for non-invasive facial rejuvenation drives innovation in neurotoxin therapies.
Conclusions:
- The success of BOTOX(R) continues to stimulate research and development in cosmetic neurotoxins.
- A growing portfolio of botulinum toxin products is emerging for aesthetic applications.
- Physician adoption and patient demand underscore the importance of these treatments in modern cosmetic practices.
More Related Videos
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:22Botulism
Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:29Tetanus
Tetanus is a life-threatening neurological disorder characterized by persistent muscle contractions and spastic paralysis. It is caused by Clostridium tetani, a motile, Gram-positive, rod-shaped, obligate anaerobe. These bacteria produce terminal endospores, giving them a distinctive “lollipop” or “tennis-racket” appearance. They thrive in anaerobic environments, such as those found in deep puncture wounds.Once introduced into the body, the spores germinate into vegetative cells. These cells...
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...